Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 8/2009

01-08-2009 | Original Paper

Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer

Authors: Alex Xiu-Cheng Fan, Ramin Radpour, Mahdi Montazer Haghighi, Corina Kohler, Peng Xia, Sinuhe Hahn, Wolfgang Holzgreve, Xiao Yan Zhong

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2009

Login to get access

Abstract

Introduction

We develop a multiplex quantitative real-time PCR for synchronized analysis of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) to investigate relative mtDNA abundance in paired normal and cancerous breast tissues.

Materials and methods

The amounts of nDNA and mtDNA in 102 tissue samples were quantified for both glyceraldehype-3-phosphodehydrogenase (GAPDH) gene and mtDNA encoded ATPase (MTATP) 8 gene. The average threshold cycle (Ct) number values of the nDNA and mtDNA were used to calculate relative mtDNA content in breast tissues.

Results

The median delta Ct (ΔCt) and the median mtDNA content for normal and cancerous breast tissues were 6.73 and 2.54, as well as 106.50 and 5.80 (P = 0.000, respectively). The mtDNA content was decreased in 82% of cancerous breast tissues compared with the normal ones. The changes were associated with hormone receptor status.

Conclusion

Our finding suggests that decreased mtDNA content in breast cancer may have diagnostic and prognostic value for the disease.
Literature
go back to reference Ellinger J, Muller SC, Wernert N, von Ruecker A, Bastian PJ (2008) Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. BJU Int 102(5):628–632PubMedCrossRef Ellinger J, Muller SC, Wernert N, von Ruecker A, Bastian PJ (2008) Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. BJU Int 102(5):628–632PubMedCrossRef
go back to reference Jain KK (2007) Cancer biomarkers: current issues and future directions. Curr Opin Mol Ther 9:563–571PubMed Jain KK (2007) Cancer biomarkers: current issues and future directions. Curr Opin Mol Ther 9:563–571PubMed
go back to reference Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA (2005) Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 207:436–444. doi:10.1002/path.1863 PubMedCrossRef Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA (2005) Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 207:436–444. doi:10.​1002/​path.​1863 PubMedCrossRef
go back to reference Masuyama M, Iida R, Takatsuka H, Yasuda T, Matsuki T (2005) Quantitative change in mitochondrial DNA content in various mouse tissues during aging. Biochim Biophys Acta 1723:302–308PubMed Masuyama M, Iida R, Takatsuka H, Yasuda T, Matsuki T (2005) Quantitative change in mitochondrial DNA content in various mouse tissues during aging. Biochim Biophys Acta 1723:302–308PubMed
go back to reference Mizumachi T, Naito MLA, Furusawa J, Fan CY, Siegel ER et al (2008b) Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate 68:408–417. doi:10.1002/pros.20697 PubMedCrossRef Mizumachi T, Naito MLA, Furusawa J, Fan CY, Siegel ER et al (2008b) Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate 68:408–417. doi:10.​1002/​pros.​20697 PubMedCrossRef
go back to reference Webb P (1986) 24-hour energy expenditure and the menstrual cycle. Am J Clin Nutr 44:614–619PubMed Webb P (1986) 24-hour energy expenditure and the menstrual cycle. Am J Clin Nutr 44:614–619PubMed
go back to reference Ye C, Shu XO, Wen W, Pierce L, Courtney R, Gao YT et al (2008) Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases. Breast Cancer Res Treat 108:427–434. doi:10.1007/s10549-007-9613-9 PubMedCrossRef Ye C, Shu XO, Wen W, Pierce L, Courtney R, Gao YT et al (2008) Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases. Breast Cancer Res Treat 108:427–434. doi:10.​1007/​s10549-007-9613-9 PubMedCrossRef
go back to reference Yin PH, Lee HC, Chau GY, Wu YT, Li SH, Lui WY et al (2004) Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer 90:2390–2396PubMed Yin PH, Lee HC, Chau GY, Wu YT, Li SH, Lui WY et al (2004) Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer 90:2390–2396PubMed
Metadata
Title
Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer
Authors
Alex Xiu-Cheng Fan
Ramin Radpour
Mahdi Montazer Haghighi
Corina Kohler
Peng Xia
Sinuhe Hahn
Wolfgang Holzgreve
Xiao Yan Zhong
Publication date
01-08-2009
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 8/2009
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-008-0533-9

Other articles of this Issue 8/2009

Journal of Cancer Research and Clinical Oncology 8/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.